Anti-CD19 CAR-T cell therapy in relapsed/refractory t(8;21) acute myeloid leukemia with aberrant CD19 expression
Considering the short-term remission of CD19 CAR-T cell therapy in R/R t(8;21) AML, allo-HSCT might be performed as soon as possible to consolidate the efficacy of CAR-T cell therapy and reduce the risk of relapse.
Authors
- Xiaomin Zhang (ORCID: https://orcid.org/0000-0003-4368-8629)
- Jingqiao Qiao (ORCID: https://orcid.org/0009-0000-1877-0044)
- Huixin Peng (ORCID: https://orcid.org/0009-0008-3623-2459)
- Jun-Hui Mei (ORCID: https://orcid.org/0000-0003-0940-5808)
- Ziren Chen
- Jiading Qin (ORCID: https://orcid.org/0000-0003-1688-3808)
- Yuanyuan Zheng (ORCID: https://orcid.org/0000-0002-7595-1375)
- Lixin Wang (ORCID: https://orcid.org/0000-0002-9986-9712)
- Yu Li (ORCID: https://orcid.org/0000-0001-8578-7268)
- Rui Li (ORCID: https://orcid.org/0000-0001-8353-6772)
- Hongxin Wang (ORCID: https://orcid.org/0000-0001-5531-3109)
- Wenfa Huang (ORCID: https://orcid.org/0000-0002-9134-3134)
- Shuhong Wang (ORCID: https://orcid.org/0000-0001-7624-478X)
- Lijun Wang (ORCID: https://orcid.org/0000-0003-3990-6902)
- Yisheng Li
- Chuan Yu
Institutions
- Beike Biotechnology (China) (CN)
- Shenzhen University Health Science Center (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-07-21
- DOI
- https://doi.org/10.3389/fimmu.2025.1617589
- Citations
- 3
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 3.14
Funders
- National Natural Science Foundation of China
- Shenzhen University
- Sanming Project of Medicine in Shenzhen
- Shenzhen Key Laboratory Fund